Investing.com - ProQR Therapeutics NV reported on Wednesday third quarter earnings that missed analysts' forecasts and revenue that topped expectations.
ProQR Therapeutics NV announced earnings per share of €-0.340 on revenue of €956K. Analysts polled by Investing.com anticipated EPS of €-0.211 on revenue of €838.96K.
ProQR Therapeutics NV shares are down 28.9% from the beginning of the year , still down 89.71% from its 52 week high of €8.60 set on Tuesday, January 4, 2022.
ProQR Therapeutics NV shares lost 4.22% in intra-day trade the report.
ProQR Therapeutics NV follows other major Healthcare sector earnings this month
ProQR Therapeutics NV's report follows an earnings beat by UnitedHealth on Friday, October 14, 2022, who reported EPS of €5.79 on revenue of €80.89B, compared to forecasts EPS of €5.43 on revenue of €80.52B.
J&J had beat expectations on Tuesday, October 18, 2022 with third quarter EPS of €2.55 on revenue of €23.79B, compared to forecast for EPS of €2.52 on revenue of €23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar